U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Showing 1 - 10 of 177 results

Status:
US Approved Rx (2020)
First approved in 2020

Class (Stereo):
CHEMICAL (RACEMIC)


Conditions:

Amisulpride, a benzamide derivative, shows a unique therapeutic profile being atypical antipsychotic. At low doses, it enhances dopaminergic neurotransmission by preferentially blocking presynaptic dopamine D2/D3 autoreceptors. At higher doses, amisu...
Status:
US Approved Rx (2018)
First approved in 2018

Class (Stereo):
CHEMICAL (ABSOLUTE)



Cannabidiol is the major nonpsychoactive ingredient in cannabis. Cannabidiol demonstrates a range of effects that may be therapeutically useful, including anti-seizure, antioxidant, neuroprotective, anti-inflammatory, analgesic, anti-tumor, anti-psy...
Status:
US Approved Rx (2025)
First approved in 2015

Class (Stereo):
CHEMICAL (ACHIRAL)



Brexpiprazole is a novel D2 dopamine and serotonin 1A partial agonist, called serotonin-dopamine activity modulator (SDAM), and a potent antagonist of serotonin 2A receptors, noradrenergic alpha 1B and 2C receptors. Brexpiprazole is approved for the ...
Status:
US Approved Rx (2015)
First approved in 2015

Class (Stereo):
CHEMICAL (ABSOLUTE)



Cariprazine is an antipsychotic approved by FDA for the treatment of schizophrenia and bipolar I disorder. The drug has a unique clinical action which is explained by its ability to act on dopamine D3 receptors. Pharmacology studies revealed that car...
Status:
US Approved Rx (2015)
First approved in 2015

Class (Stereo):
CHEMICAL (ACHIRAL)



Flibanserin is the first drug to be approved for hypoactive sexual desire disorder (HSDD) in premenopausal women by the FDA in August 2015. It was originally developed as an antidepressant medication by Boehringer Ingelheim, but showed lack of effica...
Status:
US Approved Rx (2020)
First approved in 2011

Class (Stereo):
CHEMICAL (ACHIRAL)



Vilazodone is a serotonergic antidepressant. The mechanism of the antidepressant effect of vilazodone is not fully understood but is thought to be related to its inhancement of serotonergic activity in the CNS through selective inhibition of serotoni...
Status:
US Approved Rx (2009)
First approved in 2009

Class (Stereo):
CHEMICAL (ACHIRAL)


Conditions:

Iloperidone, also known as Fanapt, Fanapta, and previously known as Zomaril, is an atypical antipsychotic for the treatment of schizophrenia. Iloperidone shows high affinity and maximal receptor occupancy for dopamine D2 receptors in the caudate nucl...
Status:
US Approved Rx (2007)
First approved in 2007

Class (Stereo):
CHEMICAL (ABSOLUTE)



Rotigotine is an agonist at all 5 dopamine receptor subtypes (D1-D5) but binds to the D3 receptor with the highest affinity. It is also an antagonist at α-2-adrenergic receptors and an agonist at the 5HT1A receptors. Rotigotine also inhibits dopamine...
Status:
US Approved Rx (2015)
First approved in 2002

Class (Stereo):
CHEMICAL (ACHIRAL)



Aripiprazole is the first next-generation atypical antipsychotic. The unique actions of aripiprazole in humans are likely a combination of "functionally selective" activation of D(2) (and possibly D(3))-dopamine receptors and serotonin 5-HT(1A) recep...
Status:
US Approved Rx (2019)
First approved in 2001

Class (Stereo):
CHEMICAL (ACHIRAL)



Ziprasidone is atypical antipsychotic, approved by the U.S. Food and Drug Administration for the treatment of schizophrenia, and acute mania and mixed states associated with bipolar disorder. Intramuscilar injections of Ziprasidone are indicated for ...